These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35921522)

  • 21. Identifying key determinants and dynamics of SARS-CoV-2/ACE2 tight interaction.
    Ngo VA; Jha RK
    PLoS One; 2021; 16(9):e0257905. PubMed ID: 34582502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
    Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
    Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
    Yang Y; Du Y; Kaltashov IA
    Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.
    Xie F; Su P; Pan T; Zhou X; Li H; Huang H; Wang A; Wang F; Huang J; Yan H; Zeng L; Zhang L; Zhou F
    Adv Mater; 2021 Dec; 33(49):e2103471. PubMed ID: 34665481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
    Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus.
    Ashoor D; Ben Khalaf N; Marzouq M; Jarjanazi H; Chlif S; Fathallah MD
    Front Cell Infect Microbiol; 2021; 11():707194. PubMed ID: 34434902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
    Feng L; Fu S; Zhang P; Zhang Y; Zhao Y; Yao Y; Luo L; Ping P
    Front Public Health; 2022; 10():1050034. PubMed ID: 36518573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
    Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
    J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
    Borkotoky S; Dey D; Hazarika Z
    Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor.
    Taka E; Yilmaz SZ; Golcuk M; Kilinc C; Aktas U; Yildiz A; Gur M
    J Phys Chem B; 2021 Jun; 125(21):5537-5548. PubMed ID: 33979162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
    Corrêa Giron C; Laaksonen A; Barroso da Silva FL
    Virus Res; 2020 Aug; 285():198021. PubMed ID: 32416259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design.
    Sorokina M; M C Teixeira J; Barrera-Vilarmau S; Paschke R; Papasotiriou I; Rodrigues JPGLM; Kastritis PL
    Sci Data; 2020 Sep; 7(1):309. PubMed ID: 32938937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interfacial Water in the SARS Spike Protein: Investigating the Interaction with Human ACE2 Receptor and In Vitro Uptake in A549 Cells.
    Singh AV; Kayal A; Malik A; Maharjan RS; Dietrich P; Thissen A; Siewert K; Curato C; Pande K; Prahlad D; Kulkarni N; Laux P; Luch A
    Langmuir; 2022 Jul; 38(26):7976-7988. PubMed ID: 35736838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of an engineered ACE2 as a novel therapeutics against COVID-19.
    Payandeh Z; Rahbar MR; Jahangiri A; Hashemi ZS; Zakeri A; Jafarisani M; Rasaee MJ; Khalili S
    J Theor Biol; 2020 Nov; 505():110425. PubMed ID: 32735992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
    El-Shennawy L; Hoffmann AD; Dashzeveg NK; McAndrews KM; Mehl PJ; Cornish D; Yu Z; Tokars VL; Nicolaescu V; Tomatsidou A; Mao C; Felicelli CJ; Tsai CF; Ostiguin C; Jia Y; Li L; Furlong K; Wysocki J; Luo X; Ruivo CF; Batlle D; Hope TJ; Shen Y; Chae YK; Zhang H; LeBleu VS; Shi T; Swaminathan S; Luo Y; Missiakas D; Randall GC; Demonbreun AR; Ison MG; Kalluri R; Fang D; Liu H
    Nat Commun; 2022 Jan; 13(1):405. PubMed ID: 35058437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
    Glasgow A; Glasgow J; Limonta D; Solomon P; Lui I; Zhang Y; Nix MA; Rettko NJ; Zha S; Yamin R; Kao K; Rosenberg OS; Ravetch JV; Wiita AP; Leung KK; Lim SA; Zhou XX; Hobman TC; Kortemme T; Wells JA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28046-28055. PubMed ID: 33093202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.